EB 101 - Abeona Therapeutics

Drug Profile

EB 101 - Abeona Therapeutics

Alternative Names: Epidermolysis bullosa gene therapy - Abeona therapeutics; LEAES; LZRSE COL7A1; LZRSE-Col7A1 Engineered Autologous Epidermal Sheets

Latest Information Update: 01 Jun 2017

Price : $50

At a glance

  • Originator Stanford University
  • Developer Abeona Therapeutics; Epidermolysis Bullosa Research Partnership; Stanford University
  • Class Gene therapies; Skin disorder therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Epidermolysis bullosa

Most Recent Events

  • 30 May 2017 EB 101 receives Rare Pediatric Disease Designation from the US FDA for Epidermolysis bullosa
  • 25 May 2017 EB 101 - Abeona Therapeutics receives Orphan Drug status for Epidermolysis bullosa in USA
  • 02 May 2017 Updated efficacy and pharmacodynamics data from a phase I/II trial in Epidermolysis bullosa released by Abeona Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top